dc.description.abstract | Severe malarial anemia (SMA) is a leading cause of morbidity and mortality in children residing in regions where Plasmodium falciparum transmission is holoendemic. Although largely unexplored in children with SMA, interleukin-18 (IL-18) is important for regulating innate and acquired immunity in inflammatory and infectious diseases. As such, we selected two functional single-nucleotide polymorphisms (SNPs) in the IL-18 promoter ( 137G3C [rs187238] and 607C3A [rs1946518]) whose haplotypes encompass significant genetic variation due to the presence of strong linkage disequilibrium among these variants. The relationship between the genotypes/haplotypes, SMA (hemoglobin [Hb], <5.0 g/dl], and longitudinal clinical outcomes were then investigated in Kenyan children (n 719). Multivariate logistic regression analyses controlling for age,
gender, sickle cell trait, glucose-6-phosphate dehydrogenase (G6PD) deficiency, HIV-1, and bacteremia revealed
that carriage of the 607AA genotype was associated with protection against SMA (odds ratio [OR] 0.440 [95% confidence interval {CI} 0.21 to 0.90], P 0.031) in children with acute infection. In contrast, carriers of the 137G/ 607C (GC) haplotype had increased susceptibility to SMA (OR 2.050 [95% CI 1.04 to 4.05], P 0.039). Measurement of IL-18 gene expression in peripheral blood leukocytes demonstrated that elevated IL-18 transcripts were associated with reduced hemoglobin concentrations ( 0.293, P 0.010) and that carriers of the “susceptible” GC haplotype had elevated IL-18 transcripts (P 0.026). Longitudinal investigation of clinical outcomes over a 3-year follow-up period revealed that carriers of the rare CC haplotype ( 1% frequency) had 5.76 times higher mortality than noncarriers (P 0.001). Results presented here demonstrate that IL-18 promoter haplotypes that condition elevated IL-18 gene products during acute infection are associated with increased risk of SMA. Furthermore, carriage of the rare CC haplotype significantly increases the risk of childhood mortality. | en_US |